Multiagent chemotherapy in relapsing ovarian cancer

Area of Science:

• Oncology
• Medical Research

Background:

• Relapsing epithelial ovarian cancer presents a significant treatment challenge.
• Previous therapies, including alkylating agents and Adriamycin, were often ineffective in recurrent cases.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel multiagent chemotherapy regimen in patients with relapsing epithelial ovarian cancer.
• To assess the response rate and duration of remission in a heavily pretreated patient population.

Main Methods:

• A combination of vinblastine, bleomycin, hexamethylmelamine, and cis-platinum was administered to 36 patients.
• Treatment design incorporated data from a human tumor stem cell assay.
• Patients had relapsing disease after prior alkylating agent and/or Adriamycin therapy.

Main Results:

• An overall response rate of 49% was observed, with 8 complete remissions and 9 partial remissions among 35 evaluable patients.
• The median duration of response was 10 months.
• Mild to moderate peripheral neuropathy (11%) was the primary side effect; myelotoxicity was manageable.

Conclusions:

• The four-drug regimen demonstrates significant efficacy in heavily pretreated patients with relapsing ovarian cancer.
• This combination chemotherapy warrants further investigation as a potential first-line treatment for previously untreated ovarian cancer patients.